Survival-Related lncRNA Landscape Analysis Identifies LINC01614 as an Oncogenic lncRNA in Gastric Cancer

Abstract

Background: Long non-coding RNAs (lncRNAs) reportedly play important roles in biomarker and tumorigenesis of gastric cancer (GC). This study aimed to determine the potential application of prognostic lncRNA signature and identified the role of LINC01614 in carcinogenesis in GC.Material and Methods: Data accessed from the Cancer Genome Atlas database was used to construct a lncRNA signature. Joint effect analysis of the signature and clinical parameters was performed to verify the clinical value of the signature. Co-expression analysis was conducted for prognostic lncRNAs and protein-coding genes. Moreover, the relative expression of LINC01614 was validated in GC tissues and cell lines. In vitro and in vivo experiments were conducted to analyze the biological functions of the newly identified gene in GC cells.Results: A seven-lncRNA (LINC01614, LINC01537, LINC01210, OVAAL, LINC01446, CYMP-AS1, and SCAT8) signature was identified as a promising prognostic signature in GC. Results indicated that the seven-lncRNA was involved in tumorigenesis and progression pathways. LINC01614 expression was identified and found to be upregulated in GC tissues and cells. The study findings revealed that LINC01614 promoted cell proliferation, migration, invasion, and epithelial-mesenchymal transition. Knockdown of LINC01614 arrested cell cycle distribution at the G2/M phase. Further, LINC01614 also promoted tumor growth in vivo.Conclusion: We developed an independent seven-lncRNA biomarker for prognostic prediction and identified LINC01614 as an oncogenic lncRNA in GC.

A prognostic signature of pyroptosis-related lncRNAs verified in gastric cancer samples to predict the immunotherapy and chemotherapy drug sensitivity

“…Herein, we established that PVT1 expression was remarkably increased in GC tissues, which is consistent with previous studies. Wu et al demonstrated that CYMP-AS1 can be used as a biomarker for GC ( Wu H. et al, 2021 ), which further makes our model more convincing. However, AC017076.1 was less studied.…”

Risk SNP‐mediated LINC01614 upregulation drives head and neck squamous cell carcinoma progression via PI3K/AKT signaling pathway

“…To date, plenty of evidence has corroborated the oncogenic role of LINC01614 in various types of cancers, including lung cancer, breast cancer, glioma, osteosarcoma, bladder cancer, thyroid carcinoma, and gastric cancer 36,37,62–65 . Recently, Wang et al's 39 study revealed that LINC01614 may be an oncogene and a credible diagnostic and prognostic biomarker for many cancers, including HNC.…”

“…Yan et al's 30 study illustrated that rs6695584 in LncSLCC1 changed the protein-binding motif of BATF, altered the enhancer activity, and subsequently activated LncSLCC1 expression. Therefore, the biological function of rs16854802 needs further research.To date, plenty of evidence has corroborated the oncogenic role of LINC01614 in various types of cancers, including lung cancer, breast cancer, glioma, osteosarcoma, bladder cancer, thyroid carcinoma, and gastric cancer 36,37,[62][63][64][65]. Recently, Wang et al's39 study revealed that LINC01614 may be an oncogene and a credible diagnostic and prognostic biomarker for many cancers, including HNC.…”

Identification and validation of a novel angiogenesis-related gene signature for predicting prognosis in gastric adenocarcinoma

“…LncRNA SLC1A5 may be a novel prognostic marker and a potential target for STAD immunotherapy in the future ( 30 ). Although several lncRNA biomarkers were found to help predict the overall survival of patients with STAD, panels of lncRNA biomarkers may be better optimized than single lncRNAs ( 31 , 32 ).…”